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Immunoglobulin G (IgG) has been implicated in the progression of various cancers.
This study explored the role of IgG in the proliferation, apoptosis, cell cycle and
in vitro invasive properties of LNCaP prostate cancer cells. We used IGHG1 small
interfering RNA to silence IgG1 expression in LNCaP cells. The efficacy of IgG1 gene
knockdown was confirmed using qPCR and western blotting. The colony formation,
proliferation, migration and invasion abilities of LNCaP cells after transfection were
assessed using colony-forming, flow cytometry and transwell assays. The expressions
of PCNA and caspase-3 proteins in LNCaP cells after transfection were detected with
immunofluorescence staining and western blotting. IgG1 silencing significantly
decreased the colony formation, survival, cell cycle progression, migration and
invasion of LNCaP cells (p < 0.05). IgG1 silencing also reduced the amount of the
proliferation marker PCNA and induced formation of the apoptotic marker caspase-3
(p < 0.05). Our results show that IgG1 produced by LNCaP cells confers advantages
for tumor cell survival, proliferation, migration and invasion, suggesting that IgG1 is a
potential target for prostate cancer treatment.
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Prostate cancer accounts for approximately 25% of new cancer diagnoses and is the
second leading cause of cancer-related death in men [1, 2]. The incidence of prostate
cancer varies by region and ethnicity. In China, prostate cancer is often diagnosed
when patients have already reached advanced stages of the disease, so the tumors are
not amenable to surgical resection [1, 3]. Often, the only recourse is systemic treat-
ment that includes androgen deprivation therapy (targeting the androgen receptor
pathway), chemotherapy, bone-directed therapy, radiation therapy or a combination of
these treatments [4]. There is a high rate of recurrence and resistance to therapies
often develops over time, so there is a strong need to identify additional novel molecu-
lar targets for alternative therapeutic strategies.
Immunoglobulins (Ig) are expressed by B lymphocytes and a variety of tumor tissues
and cancer cell lines including breast, cervical, lung, hepatic, prostate and oral epithe-
lial tumors [5–10]. Immunoglobulin G (IgG) accounts for 75–80% of the total Ig pool© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
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IgG in promoting cancer progression [12–14]. In lung cancer, breast cancer and
esophageal squamous cell carcinomas, tumor-derived IgG not only enhances the
growth and survival of cancer cells but also facilitates metastatic processes.
It is possible that IgG has pro-tumor effects due to its role in the immune system.
For example, in papillary thyroid cancer, IgG co-localized with complement proteins,
which may indicate the formation of immune complexes that allow the cancer cells to
escape host immune responses [15]. However, high levels of endogenous IgG in the
serum might also impair NK cell-mediated antibody-dependent cell cytotoxicity in
antibody-based therapy [16, 17].
Alternative roles of IgG that are not related to immune function should also be con-
sidered in cancer cells. To date, relatively little is known about the role of prostate
cancer-derived Ig. In prostate cancer patients, the serum levels of IgG, IgA or IgM are
usually elevated [18, 19]. However, whether IgG exists intracellularly in tumor cells is a
controversial question [10, 20]. Chen et al. found IgG heavy and light chain proteins lo-
calized in the cytoplasm and at the membrane of prostate cancer cells using the PC3
cell line [5]. They also documented expression of recombination activating gene 1
(RAG1) and RAG2. Consistent with their findings, we also found IgG expression in
PC3 cells and in another prostate cancer cell line, LNCaP, in an earlier study [21].
LNCaP cells are hormone-dependent cancer cells that are typical of early-stage pros-
tate cancer. This study aimed to address the role of IgG in prostate cancer using
LNCaP cells. The method involved silencing IgG expression using RNA interference
(RNAi) technology. Tumor cell survival advantages are conferred by a variety of mech-
anisms, including increased cell proliferation, cell cycle dysregulation and apoptosis
resistance. Therefore, we assessed the effects of IgG knockdown on each of these
outcomes, and on the migration and invasion abilities of LNCaP prostate cancer cells.Materials and methods
Cell culture
Human androgen-dependent prostate cancer cells from the LNCaP line were obtained
from Landbiology. The cells were maintained in Dublecco’s modified Eagle’s medium
(DMEM; Hyclone) supplemented with 10% fetal bovine serum (FBS; Hyclone) at 37 °C
in a humidified 5% CO2 atmosphere. Cells were used in the logarithmic growth phase.Transfection
The siRNA oligoribonucleotides were designed and synthesized by RiboBio. The
siRNAs targeting human IgG1 mRNA were termed siIgG. siRNA that was not hom-
ologous to any human genome sequences was used as the negative control and
termed siCon. The siIgG sequence targeted the constant region of the IgG1 heavy
chain (target sequence: CTACACATCAGCAGGAATA). The sequences of the sense
and anti-sense strands were 5′-CUACACAUCAGCAGGAAUA and 3′-dTdTGAU-
GUGUAGUCGUCCUUAU, respectively. The day prior to transfection, LNCaP cells
were seeded on 6-well plates (5.0 × 105 cells/well) or 96-well plates (1.0 × 104 cells/
well). The cells were allowed to grow until they were 70–80% confluent and then
transfected with duplex siRNA using Lipofectamine 2000 (Invitrogen) according to
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tative PCR (qPCR) 36 h after transfection.
RNA isolation and qPCR
Total RNA was extracted using TRIzol (Invitrogen). cDNA was synthesized from 1 μg of
RNA using the M-MLV reverse transcriptase system (Promega) according to the manufac-
turer’s instructions. The qPCR reaction contained 5 μl cDNA (1:20), 0.5 μl forward primer,
0.5 μM reverse primer, 10 μl 2× SYBR Green qPCR SuperMix (PE Applied Biosystems) and
4 μl ddH2O. qPCR was performed using an ABI Prism 7500 Sequence Detection System
(Applied Biosystems). The reaction conditions were 95 °C for 5 min followed by 40 cy-
cles consisting of 95 °C for 15 s, 60 °C for 15 s and 72 °C for 32 s. The sequences of
the IGHG1 primers were: forward 5′-GCAGCCGGAGAACAACTACA-3′ and reverse
5′-TGGTTGTGCAGAGCCTCATG-3′. 18SrRNA was used as the internal reference (for-
ward primer: 5′-CCTGGATACCGCAGCTAGGA-3′, reverse primer: 5′-GCGGCGCAA
TACGAATGCCCC-3′). Relative quantitation was performed using the ΔΔCt method.
Western blotting
Total cell lysates were prepared and then separated using SDS-PAGE and transferred
to a PVDF membrane (Millipore). The membranes were then blocked with 5% skim
milk at room temperature for 1 h. The membranes were washed and incubated with
primary antibody at 37 °C for 2 h and secondary antibody at 37 °C for 1 h. The primary
antibodies used were: rabbit anti-human IgG (Dako) and horseradish peroxidase-
conjugated anti-GAPDH (KangChen Bio-tech). The secondary antibodies used were:
horseradish peroxidase-conjugated goat anti-rabbit and anti-mouse IgG (Dako). After
washing, the proteins were visualized using the SuperSignal West Pico Chemilumines-
cent Substrate Kit (Pierce Biotechnology) according to the manufacturer’s instructions.
Densitometry analysis was performed using AlphaImager 2200 analysis software.
Colony-forming assay
Three groups of cells were plated in triplicate at 100 cells per well in 96-well plates.
One the cells had formed colonies, they were stained with crystal violet and then
photographed and counted. Experiments were independently repeated three times and
the results were quantified as colony-forming efficiency (CFE) and surviving fraction
(SF) using the equations:
CFE ¼ number of colonies=number of inoculated cells  100%
SF ¼ number of experimental group colonies=number of control group colonies
 100%
Cell cycle analysis
Cells were collected 48 h after transfection and fixed with 70% ethanol at 4 °C over-
night. The cells were then stained with a cell cycle detection kit (KeyGen Bio-tech).
Briefly, after one washing with PBS, the fixed cells were re-suspended in 500 μl PBS
containing 50 μg/ml propidium iodide (PI), 100 μg/ml RNase A and 0.2% Triton X-100
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(BD Biosciences) using the ModFit software.Cell migration and invasion assays
For the migration assays, 105 cells in 100 μl of serum-free medium were placed into
the upper chamber of a transwell insert (BD Biosciences). For the invasion assays, 105
cells in 100 μl serum-free medium were placed into the upper chamber of a transwell
insert coated with Matrigel (BD Biosciences). Medium supplemented with 10% FBS
(600 μl) was added to the lower chamber. The transwell plates were incubated at 37 °C
in 5% CO2 for 12–48 h. The cells remaining on the upper membrane were removed
with cotton wool. The cells that had migrated or invaded through the membrane were
fixed with 4% paraformaldehyde, stained with crystal violet for 10 min, imaged and
counted. Experiments were independently repeated three times.Immunofluorescence staining
Cells were grown on slides, transfected with siIgG or siCon, and 48 h later, fixed with
4% paraformaldehyde for 30 min at room temperature. After washing, the fixed cells
were permeabilized with 0.2% Triton-X 100 for 5 min at room temperature, then
blocked with 10% normal goat serum for 30 min, and incubated with primary anti-
bodies against proliferating cell nuclear antigen (PCNA; Cell Signaling Technology)
and caspase-3 (Abcam) at 4 °C overnight. The following day, the slides were incubated
with fluorescently labeled secondary antibody (1:200; Life Technologies) in the dark for
1 h and 4′,6-diamidino-2-phenylindole (DAPI) for 5 min. Slides were mounted with
antifade mounting medium (Beyotime). The slides were imaged and analyzed using
Image-Pro Plus software (Media Cybernetics).Statistical analysis
All data are expressed as means ± standard deviation and reflect at least three independent
experiments. One-way ANOVA and Tukey’s post-hoc test were used to compare the
means of the three groups (LNCaP, siCon and siIgG). A p-value less than 0.05 was consid-
ered significant. All analyses were done with IBM SPSS Version 20 (SPSS Statistics V20,
IBM Corporation).Results
IgG1 knockdown inhibited the attachment-independent growth of LNCaP cells
To investigate the role of IgG, LNCaP cells were transfected with siCon or siIgG to
knockdown IgG1 expression. LNCaP cells that were not transfected with any siRNA
were used as a second control group (LNCaP). The reduction in IgG1 was confirmed
at the mRNA level via qPCR (Fig. 1a) and at the protein level via western blotting
(Fig. 1b). IgG1 mRNA expression in the siIgG group (0.11 ± 0.03) was significantly (p <
0.01) lower than the expression in either the siCon (1 ± 0.25) or LNCaP (0.94 ± 0.06)
groups. Similarly, IgG1 protein expression in the siIgG group (1.02 ± 0.09) was signifi-
cantly (p < 0.01) lower than the expression in either the siCon (3.03 ± 0.11) or LNCaP
(2.9 ± 0.21) groups. The IgG1 mRNA and protein expression levels in the siCon and
LNCaP groups were not significantly (p > 0.05) different.
Fig. 1 IGHG1 silencing suppresses the clonogenicity and survival of LNCaP cells. Cells were transfected with
IgG1 (siIgG) and control siRNA (siCon). a – Cells were harvested at 36 h for qPCR to determine the mRNA
expression levels. b – Cells were harvested at 48 h for western blotting to determine the protein expression
levels. c – Transfected cells were used for a colony-forming assay. Colonies were stained with crystal violet and
then counted to calculate the colony-forming efficiency (CFE). d – The same stained colonies were counted to
determine the surviving fraction (SF). *p < 0.01 vs. siCon; #p < 0.01 vs. LNCaP (non-transfected control)
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to form attachment-independent colonies (Fig. 1c) and on survival (Fig. 1d) were ana-
lyzed with colony-forming assays. The colony-forming efficiency (CFE) and surviving
fraction (SF) of the siIgG group were significantly (p < 0.05) lower than the values for
either of the two control groups 48 h after transfection.
These results indicated that the siRNA approach successfully reduced the expression
of IgG1 at the mRNA and protein levels, and that reduced IgG1 expression impaired
the ability of LNCaP cells to survive and form colonies.IgG1 knockdown inhibited cell cycle progression in LNCaP cells
The effects of siRNA-mediated downregulation of IgG1 on cell cycle progression were
examined via flow cytometry 48 h after transfection in cells stained with PI (Fig. 2a).
Quantitative results are shown in Fig. 2b. The percentage of cells in the G1 phase in
the siIgG group (75.88 ± 0.55) was significantly (p < 0.05) higher than the percentage for
either the siCon (64.74 ± 0.29) or LNCaP (64.53 ± 0.35) groups. Concurrently, the percent-
age of cells in the S phase in the siIgG group (17.06 ± 0.35) was significantly (p < 0.05)
lower than either the siCon (28.63 ± 2.09) or LNCaP (28.17 ± 0.17) groups, indicating that
IgG1 knockdown blocked cell cycle progression.IgG1 knockdown inhibited migration and invasion of LNCaP cells
Transwell experiments were performed to further investigate whether IgG1 knock-
down affected the ability of LNCaP cells to migrate and invade. Representative im-
ages showing the number of cells migrating through the transwell (Fig. 3a) and
invading the Matrigel substrate (Fig. 3b) are shown. Quantitative results indicated
that the number of cells with the ability to migrate (Fig. 3c) and invade (Fig. 3d)
was significantly (p < 0.05) reduced in the siIgG group compared to the two control
groups. Thus, it is likely that IgG1 expression increases the migratory and invasive
potential of LNCaP cells.
Fig. 2 IGHG1 silencing attenuates the cell cycle progression of LNCaP cells. Cells were transfected with IgG1
(siIgG) and control siRNA (siCon) for 48 h, then harvested, fixed and stained with propidium iodide (PI). The
cell cycle was analyzed by flow cytometry. a – Representative histograms. b – Quantitative results from three
independent experiments. *p < 0.05 vs. siCon; #p < 0.05 vs. LNCaP (non-transfected control)
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Next, we investigated the effects of siRNA-mediated IgG1 downregulation on cell pro-
liferation and apoptosis. Proliferation was assessed via immunofluorescence staining for
the PCNA antigen in the siIgG, siCon and LNCaP groups. Figure 4a presents represen-
tative images showing the number of PCNA-positive cells in the siIgG group compared
to the control groups. Quantitative analyses indicated that the number of PCNA-
positive cells was significantly (p < 0.05) lower in the siIgG group than in either control
group (Fig. 4c). The percentage of apoptotic cells was assessed using the marker
caspase-3. Representative images of caspase-3 staining are shown in Fig. 4b. The num-
ber of caspase-3 positive cells was significantly (p < 0.05) higher in the siIgG group than
in the two control groups (Fig. 4d). These effects are consistent with the tumor
suppressive effects of IgG1 knockdown.
Discussion
Despite the progress in developing new treatments, the mortality of late-stage prostate
cancer remains high, meaning there is still a need to investigate novel therapeutics. We
and other researchers have found that IgG is expressed in prostate cancer cell lines and
prostate cancer tissues [21, 22]. This study was undertaken to understand the role of IgG
expression in the prostate cancer cell line LNCaP using siRNA to knockdown IgG1. Silen-
cing IgG increased apoptosis and inhibited proliferation, cell migration and invasion.
The mechanisms conferring tumor cell survival advantages are a complex network
involving signaling of cell proliferation, cell cycle and apoptosis [23]. Our study found
Fig. 3 IGHG1 silencing reduces in vitro migration and invasion of LNCaP cells. Cells were transfected with
IgG1 (siIgG) and control siRNA (siCon) and then seeded into transwells to determine a – The cell migration
ability and b – The cell invasion ability. For migration assays, the cells were seeded in inserts containing
fresh medium. For invasion assays, the inserts contained matrigel. Representative pictures are shown (scale
bar, 100 μM). c, d – Quantitative results from three independent experiments are shown. *p < 0.05 vs. siCon;
#p < 0.05 vs. LNCaP (non-transfected control)
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found that cell proliferation was inhibited with IgG siRNA through the downregulation
of proliferating cell nuclear antigen (PCNA), which is an auxiliary factor for DNA poly-
merase δ in eukaryotic cells and is essential for DNA replication [24]. Caspase-3 is the
main executor of the caspase cascade in apoptotic cells. It was previously shown that
pHyde, a novel gene identified in Dunning rat prostate cancer cells, induces apoptosis
in a dose-dependent manner by activating caspase-3 [25]. It is possible that the IgG1-
mediated inhibition of apoptosis involves pHyde in LNCaP cells, but that remains to be
confirmed. An additional report demonstrated that the loss of caspase-1 is potentially a
step toward aberrant apoptosis during prostate tumorigenesis [26]. Our results suggest
that silencing IgG1 may be a novel approach to increasing caspase-3, and possibly
caspase-1, to correct the loss of apoptosis in prostate cancer.
In addition to its pro-apoptotic effects, silencing IgG1 inhibited cell proliferation.
Although cancer cells have been found to express IgG, the molecular mechanisms by
which tumor-derived IgG promotes tumor growth are unclear. Several hypotheses have
been proposed.
Wang et al. found that tumor-derived IgG promotes tumor cell growth and prolifera-
tion by inducing the production of reactive oxygen species (ROS) [27]. They identified
that oxidative stress-related proteins, such as receptor of activated protein kinase C 1
(RACK1), ras-related nuclear protein (RAN) and peroxiredoxin 1 (PRDX1), were IgG-
interacting proteins in HeLa cells (cervical cancer). ROS scavengers inhibited the
Fig. 4 IGHG1 silencing decreases PCNA and increases caspase-3 in LNCaP cells. Cells were transfected with
IgG1 (siIgG) and control siRNA (siCon) for 48 h and then fixed with 4% paraformaldehyde and stained for a
– PCNA proliferation marker and b – caspase-3 apoptotic marker. Representative images are shown (scale
bar, 100 μM). c, d – The integrated optical density (IOD) of green fluorescence and the area were quantified.
*p < 0.05 vs. siCon; #p < 0.05 vs. LNCaP (non-transfected control)
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kinase/extracellular-regulated kinase (MAPK/ERK) pathway.
Alternatively, a recent study demonstrated that cancer-derived IgG promotes cervical
cancer cell proliferation by enhancing pro-inflammatory cytokine production in re-
sponse to lipopolysaccharide (LPS) binding to Toll-like receptor 4 (TLR4) [28]. Knock-
down of IgG suppressed NF-κB and MAPK phosphorylation, which in turn impaired
NF-κB nuclear translocation and the activity of NF-κB responsive elements. These data
suggest that IgG may be a novel therapeutic target for treating inflammation-mediated
cancers, including prostate cancer [29], and that tumor-derived IgG may play a similar
proinflammatory role in prostate cancer.
The pro-tumor effects of IgG may also include a role in metatstatic cancer. We found
that both cell migration and invasion were reduced when IgG1 was knocked down.
Jiang et al. also found that knockdown of IgG decreases the proliferation, migration
and attachment of lung cancer cells in vitro, and that IgG expression correlated with
metastasis-associated gene 1 (MTA1) expression and lymph node metastases in vivo
[12]. In a breast cancer model, IgG purified from the blood of breast cancer patients
stimulated muscarinic acetylcholine receptors to regulate cell migration and
metalloproteinase-9 (MMP-9) activity in the breast cancer cell line MCF7 [30]. The
molecular mechanisms might involve the phospholipase C, nitric oxide synthase and/or
protein kinase C pathways. It is not clear whether any of the pathways described are
associated with the pro-tumor functions of IgG in prostate cancer.
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in many cancer cell lines via nested RT-PCR [7]. However, the individual functions of
each Ig isotype in cancers are not clearly identified. Zheng et al. showed that the cancer
cell-derived Ig alpha heavy chain promotes access to S phase and the growth of cancer
cells [31]. Yang et al. examined the role of expression of Ig light chain, Ig kappa and Ig
lambda in colorectal cancer cells [32]. They found that Ig kappa and lambda help to
stabilize the anti-apoptotic protein Bcl-xL. Knockdown of the genes of Ig kappa and/or
Ig lambda suppresses Bcl-xL expression and induces apoptosis. The roles of other Ig
isotypes in prostate cancer remain to be addressed, as does whether IgG silencing
altered apoptosis in LNCaP cells by downregulating Bcl-xL.
In summary, knockdown of IgG expression by RNA interference inhibited cell prolif-
eration and increased apoptosis in a human prostate cancer LNCaP cell line. While
these results have implications for the role of IgG in prostate cancer progression, they
are limited to one cell line and one siRNA, and must be confirmed in other systems.
The results suggest that IgG is a potential target for a novel therapeutic strategy for
prostate cancer.
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